Compare $MYGN vs $SCTX | Chartloom

Compare

$MYGN vs $SCTX

Myriad Genetics Inc · Scribe Therapeutics Inc

MYGN

Myriad Genetics Inc

SCTX

Scribe Therapeutics Inc

Compare $MYGN vs $SCTX

Comparing Myriad Genetics Inc and Scribe Therapeutics Inc

MYGNMyriad Genetics Inc

SCTXScribe Therapeutics Inc

MYGNMyriad Genetics Inc

Market cap

$407M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.50x

Rev growth (TTM)

-3.2%

YTD performance

-29.8%

52W performance

-43.6%

FCF yield

-3.5%

SCTXScribe Therapeutics Inc

Market cap

$372M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

29.61x

Rev growth (TTM)

—

YTD performance

-2.2%

52W performance

-2.2%

FCF yield

0.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MYGN

SCTX

Detailed metrics comparison

MYGN

Myriad Genetics Inc

SCTX

Scribe Therapeutics Inc

Market Cap

MYGN$407M

SCTX$372M

Enterprise Value

MYGN$413M

SCTX$374M

Price

MYGN$4.31

SCTX$21.17

P/E Ratio

MYGNN/A

SCTXN/A

P/S Ratio

MYGN0.50x

SCTX0.00x

EV/Sales

MYGN0.51x

SCTX0.00x

EV/EBITDA

MYGN49.97x

SCTX0.00x

P/B Ratio

MYGN1.43x

SCTXN/A

P/FCF Ratio

MYGNN/A

SCTXN/A

EV/FCF

MYGN-29.05x

SCTX0.00x

PEG Ratio

MYGNN/A

SCTXN/A

Forward P/E (NTM)

MYGNN/A

SCTXN/A

Forward P/S (NTM)

MYGN0.50x

SCTX29.61x

Revenue (TTM)

MYGN$807M

SCTX$0

Revenue Growth (YoY)

MYGN-3.2%

SCTXN/A

Forward Rev Growth

MYGN5.6%

SCTX-43.3%

Gross Margin (TTM)

MYGN68.8%

SCTX0.0%

Operating Margin (TTM)

MYGN0.0%

SCTX0.0%

EBITDA Margin (TTM)

MYGN-5.0%

SCTX0.0%

Net Margin (TTM)

MYGN-14.0%

SCTX0.0%

FCF Margin (TTM)

MYGN-1.8%

SCTXN/A

Net Income (TTM)

MYGN$-113M

SCTXN/A

FCF (TTM)

MYGN$-14M

SCTX$0

EPS (TTM)

MYGN-$1.19

SCTX$0.00

ROE (TTM)

MYGN-3259.0%

SCTX0.0%

ROA (TTM)

MYGN-1639.0%

SCTX0.0%

ROIC (TTM)

MYGN-2418.0%

SCTX0.0%

Cash

MYGN$115M

SCTX$36M

Debt

MYGN$121M

SCTX$38M

Net Cash/Debt

MYGN$-6M

SCTX$-2M

Current Ratio (TTM)

MYGN2.21x

SCTX0.57x

Quick Ratio (TTM)

MYGN1.72x

SCTX0.56x

Debt/Equity (TTM)

MYGN0.40x

SCTX0.00x

Debt/Assets (TTM)

MYGN0.0%

SCTX0.0%

Interest Coverage (TTM)

MYGNN/A

SCTXN/A

Net Debt/EBITDA (TTM)

MYGN0.00x

SCTX0.00x

Beta

MYGN1.68

SCTX-2.64

52W Performance

MYGN-43.6%

SCTX-2.2%

YTD Performance

MYGN-29.8%

SCTX-2.2%

% from 52W High

MYGN-49.8%

SCTX-46.5%

% from 52W Low

MYGN57.3%

SCTX56.8%

Asset Turnover (TTM)

MYGN1.17x

SCTX0.00x

FCF Yield (TTM)

MYGN-3.5%

SCTX0.0%

Earnings Yield (TTM)

MYGN-27.7%

SCTX0.0%

Dividend Yield (TTM)

MYGNN/A

SCTXN/A

Rule of 40

MYGN-4.9

SCTX0.0

EV/GP/RG

MYGN1.67

SCTXN/A

Ticker research

View MYGN research View SCTX research

Metric	MYGN Myriad Genetics Inc	SCTX Scribe Therapeutics Inc
Market & Valuation
Market Cap	$407M	$372M
Enterprise Value	$413M	$374M
Price	$4.31	$21.17
P/E Ratio	N/A	N/A
P/S Ratio	0.50x	0.00x
EV/Sales	0.51x	0.00x
EV/EBITDA	49.97x	0.00x
P/B Ratio	1.43x	N/A
P/FCF Ratio	N/A	N/A
EV/FCF	-29.05x	0.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	0.50x	29.61x
Revenue & Growth
Revenue (TTM)	$807M	$0
Revenue Growth (YoY)	-3.2%	N/A
Forward Rev Growth	5.6%	-43.3%
Profitability
Gross Margin (TTM)	68.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-5.0%	0.0%
Net Margin (TTM)	-14.0%	0.0%
FCF Margin (TTM)	-1.8%	N/A
Net Income (TTM)	$-113M	N/A
FCF (TTM)	$-14M	$0
EPS (TTM)	-$1.19	$0.00
ROE (TTM)	-3259.0%	0.0%
ROA (TTM)	-1639.0%	0.0%
ROIC (TTM)	-2418.0%	0.0%
Financial Health
Cash	$115M	$36M
Debt	$121M	$38M
Net Cash/Debt	$-6M	$-2M
Current Ratio (TTM)	2.21x	0.57x
Quick Ratio (TTM)	1.72x	0.56x
Debt/Equity (TTM)	0.40x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	-2.64
52W Performance	-43.6%	-2.2%
YTD Performance	-29.8%	-2.2%
% from 52W High	-49.8%	-46.5%
% from 52W Low	57.3%	56.8%
Efficiency & Yields
Asset Turnover (TTM)	1.17x	0.00x
FCF Yield (TTM)	-3.5%	0.0%
Earnings Yield (TTM)	-27.7%	0.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	0.0
EV/GP/RG	1.67	N/A
Ticker research	View MYGN research	View SCTX research

Valuation

P/S Ratio

SCTX

0.00x

MYGN

0.50x

EV/FCF

MYGN

-29.05x

SCTX

0.00x

Growth & revenue

Revenue Growth TTM

MYGN

-3.2%

Forward Revenue Growth

MYGN

5.6%

SCTX

-43.3%

Profitability & performance

Gross Margin

MYGN

68.8%

SCTX

0.0%

ROE

SCTX

0.0%

MYGN

-3259.0%

FCF Yield %

SCTX

0.0%

MYGN

-3.5%

52-Week Performance

SCTX

-2.2%

MYGN

-43.6%

Detailed metrics comparison

MYGN

Myriad Genetics Inc

SCTX

Scribe Therapeutics Inc

Market Cap

MYGN$407M

SCTX$372M

Enterprise Value

MYGN$413M

SCTX$374M

Price

MYGN$4.31

SCTX$21.17

P/E Ratio

MYGNN/A

SCTXN/A

P/S Ratio

MYGN0.50x

SCTX0.00x

EV/Sales

MYGN0.51x

SCTX0.00x

EV/EBITDA

MYGN49.97x

SCTX0.00x

P/B Ratio

MYGN1.43x

SCTXN/A

P/FCF Ratio

MYGNN/A

SCTXN/A

EV/FCF

MYGN-29.05x

SCTX0.00x

PEG Ratio

MYGNN/A

SCTXN/A

Forward P/E (NTM)

MYGNN/A

SCTXN/A

Forward P/S (NTM)

MYGN0.50x

SCTX29.61x

Revenue (TTM)

MYGN$807M

SCTX$0

Revenue Growth (YoY)

MYGN-3.2%

SCTXN/A

Forward Rev Growth

MYGN5.6%

SCTX-43.3%

Gross Margin (TTM)

MYGN68.8%

SCTX0.0%

Operating Margin (TTM)

MYGN0.0%

SCTX0.0%

EBITDA Margin (TTM)

MYGN-5.0%

SCTX0.0%

Net Margin (TTM)

MYGN-14.0%

SCTX0.0%

FCF Margin (TTM)

MYGN-1.8%

SCTXN/A

Net Income (TTM)

MYGN$-113M

SCTXN/A

FCF (TTM)

MYGN$-14M

SCTX$0

EPS (TTM)

MYGN-$1.19

SCTX$0.00

ROE (TTM)

MYGN-3259.0%

SCTX0.0%

ROA (TTM)

MYGN-1639.0%

SCTX0.0%

ROIC (TTM)

MYGN-2418.0%

SCTX0.0%

Cash

MYGN$115M

SCTX$36M

Debt

MYGN$121M

SCTX$38M

Net Cash/Debt

MYGN$-6M

SCTX$-2M

Current Ratio (TTM)

MYGN2.21x

SCTX0.57x

Quick Ratio (TTM)

MYGN1.72x

SCTX0.56x

Debt/Equity (TTM)

MYGN0.40x

SCTX0.00x

Debt/Assets (TTM)

MYGN0.0%

SCTX0.0%

Interest Coverage (TTM)

MYGNN/A

SCTXN/A

Net Debt/EBITDA (TTM)

MYGN0.00x

SCTX0.00x

Beta

MYGN1.68

SCTX-2.64

52W Performance

MYGN-43.6%

SCTX-2.2%

YTD Performance

MYGN-29.8%

SCTX-2.2%

% from 52W High

MYGN-49.8%

SCTX-46.5%

% from 52W Low

MYGN57.3%

SCTX56.8%

Asset Turnover (TTM)

MYGN1.17x

SCTX0.00x

FCF Yield (TTM)

MYGN-3.5%

SCTX0.0%

Earnings Yield (TTM)

MYGN-27.7%

SCTX0.0%

Dividend Yield (TTM)

MYGNN/A

SCTXN/A

Rule of 40

MYGN-4.9

SCTX0.0

EV/GP/RG

MYGN1.67

SCTXN/A

Ticker research

View MYGN research View SCTX research

Metric	MYGN Myriad Genetics Inc	SCTX Scribe Therapeutics Inc
Market & Valuation
Market Cap	$407M	$372M
Enterprise Value	$413M	$374M
Price	$4.31	$21.17
P/E Ratio	N/A	N/A
P/S Ratio	0.50x	0.00x
EV/Sales	0.51x	0.00x
EV/EBITDA	49.97x	0.00x
P/B Ratio	1.43x	N/A
P/FCF Ratio	N/A	N/A
EV/FCF	-29.05x	0.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	0.50x	29.61x
Revenue & Growth
Revenue (TTM)	$807M	$0
Revenue Growth (YoY)	-3.2%	N/A
Forward Rev Growth	5.6%	-43.3%
Profitability
Gross Margin (TTM)	68.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-5.0%	0.0%
Net Margin (TTM)	-14.0%	0.0%
FCF Margin (TTM)	-1.8%	N/A
Net Income (TTM)	$-113M	N/A
FCF (TTM)	$-14M	$0
EPS (TTM)	-$1.19	$0.00
ROE (TTM)	-3259.0%	0.0%
ROA (TTM)	-1639.0%	0.0%
ROIC (TTM)	-2418.0%	0.0%
Financial Health
Cash	$115M	$36M
Debt	$121M	$38M
Net Cash/Debt	$-6M	$-2M
Current Ratio (TTM)	2.21x	0.57x
Quick Ratio (TTM)	1.72x	0.56x
Debt/Equity (TTM)	0.40x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	-2.64
52W Performance	-43.6%	-2.2%
YTD Performance	-29.8%	-2.2%
% from 52W High	-49.8%	-46.5%
% from 52W Low	57.3%	56.8%
Efficiency & Yields
Asset Turnover (TTM)	1.17x	0.00x
FCF Yield (TTM)	-3.5%	0.0%
Earnings Yield (TTM)	-27.7%	0.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	0.0
EV/GP/RG	1.67	N/A
Ticker research	View MYGN research	View SCTX research